Zheng Quan Shi Bao Wang·2025-09-19 04:36Group 1 - Yipinhong's subsidiary Guangzhou Yipinhong Pharmaceutical received approval from the National Medical Products Administration for a supplemental application for Oseltamivir Phosphate Capsules, allowing the addition of a 45mg specification and changes to excipient quantities and packaging materials [1] - The drug is indicated for the treatment of influenza A and B in adults and children aged 1 year and older, and for the prevention of influenza A and B in adults and adolescents aged 13 years and older [1] Group 2 - Guanghe Tong has received approval from the China Securities Regulatory Commission for the issuance of no more than 155 million overseas listed foreign shares (H shares) [2] - Zhenghai Magnetic Materials' "Zhenghai Convertible Bonds" will stop conversion after the trading session on September 19, with remaining convertible bonds being forcibly redeemed at a price of 100.5 yuan per bond [2] - Investors may face potential losses if the bonds are forcibly redeemed [2] Group 3 - Qingxin Environment plans to purchase liability insurance for the company and its directors and senior management, with a total premium not exceeding 150,000 yuan per year for a duration of 12 months [3]